A meta-analysis was conducted to assess the effectiveness of fecal lactoferrin (FL) in distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).
Seven studies with a total of 1012 patients were included, showing FL's pooled sensitivity at 78% and specificity at 94%.
The findings suggest that FL is a reliable, noninvasive marker that can help differentiate between IBD and IBS effectively.
Objective: To compare efficacy and tolerability of 7-day standard triple therapy versus 7-day levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori (H. pylori) infection.